Compare CBSH & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBSH | MIRM |
|---|---|---|
| Founded | 1865 | 2018 |
| Country | United States | United States |
| Employees | 4976 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 7.2B |
| IPO Year | 2008 | 2019 |
| Metric | CBSH | MIRM |
|---|---|---|
| Price | $58.37 | $100.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $58.28 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 773.4K | 598.0K |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | 4.39 | ★ 74.59 |
| EPS | ★ 2.06 | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $17.43 | $26.22 |
| Revenue Next Year | $3.43 | $22.04 |
| P/E Ratio | $28.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $46.99 | $63.23 |
| 52 Week High | $61.09 | $130.00 |
| Indicator | CBSH | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 49.33 | 47.86 |
| Support Level | $57.73 | $88.08 |
| Resistance Level | $60.72 | $105.20 |
| Average True Range (ATR) | 0.91 | 3.23 |
| MACD | -0.16 | 0.71 |
| Stochastic Oscillator | 39.57 | 58.39 |
Commerce Bancshares Inc operates as the bank holding company for Commerce Bank. The bank is engaged in the general banking business, providing a broad range of retail, mortgage banking, corporate, investment, trust, and asset management products and services to individuals, businesses, and municipalities. The company has three reportable segments. The Commercial segment provides lending, leasing, deposit, payment, and cash management services to business and government customers. The Retail Banking segment offers consumer deposits, consumer lending, mortgage banking, and debit and credit card services through its branch network. The Wealth segment provides trust, estate planning, brokerage, and investment management services to individual and institutional clients.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.